BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 8768004)

  • 1. [II. Leukemia in the elderly, secondary, recurrent and refractory leukemia, chloroma].
    Jehn U; Dengler R; Petrides PE
    Internist (Berl); 1996 Jun; 37(6):669-77. PubMed ID: 8768004
    [No Abstract]   [Full Text] [Related]  

  • 2. Ph-positive acute lymphoblastic leukemia after long-term remission of Ph-positive acute myeloid leukemia.
    Nishida H; Yoshimizu N; Ueno H; Fujita A; Kato T; Park JW; Yano T; Tobinai K; Ikeda Y
    Leuk Res; 2007 Mar; 31(3):417-8. PubMed ID: 16730062
    [No Abstract]   [Full Text] [Related]  

  • 3. [Acute myeloid leukemia].
    Büchner T
    Internist (Berl); 1993 Jun; 34(6):511-7. PubMed ID: 8335440
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary acute myeloid leukemia after treatment of acute monoblastic leukemia.
    Kebelmann-Betzing C; Seeger K; Kulozik A; Henze G; Liehr T; Heller A; Teigler-Schlegel A
    N Engl J Med; 2000 Dec; 343(25):1897-8. PubMed ID: 11117994
    [No Abstract]   [Full Text] [Related]  

  • 5. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology.
    Matsouka P; Pagoni M; Zikos P; Giannakoulas N; Apostolidis I; Asprogeraka T; Arvanitopoulou E; Spanoudakis E; Kotsianidis I; Tsatalas K; Papaioannou M; Marinakis T; Skandali A; Viniou N; Yataganas X; Bakiri M
    Ann Hematol; 2006 Apr; 85(4):250-6. PubMed ID: 16416114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary parotid mucoepidermoid carcinoma after TBI and chemotherapy in childhood AML.
    Piccinelli KJ; Taj M; Lucraft HH; Skinner R
    Pediatr Blood Cancer; 2006 Sep; 47(3):345-6. PubMed ID: 16572403
    [No Abstract]   [Full Text] [Related]  

  • 8. The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
    Pagano L; Mele L; Voso MT; Chiusolo P; Putzulu R; Mazzotta S; Leone G
    Haematologica; 2001 Apr; 86(4):440-1. PubMed ID: 11325656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Special clinical concerns/problems in the management of MDS and secondary acute myeloid leukemias.
    Venugopal P; Manson S; Preisler HD
    Cancer Treat Res; 2001; 108():257-65. PubMed ID: 11702603
    [No Abstract]   [Full Text] [Related]  

  • 10. Relapse and death during first remission in acute myeloid leukemia.
    Yanada M; Garcia-Manero G; Borthakur G; Ravandi F; Kantarjian H; Estey E
    Haematologica; 2008 Apr; 93(4):633-4. PubMed ID: 18379012
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine.
    Kuendgen A; Gräf T; Zohren F; Hildebrandt B; Hünerlitürkoglu A; Gattermann N; Haas R; Kobbe G
    Leuk Res; 2007 Mar; 31(3):407-9. PubMed ID: 16890286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
    Hatoum HA; Mahfouz RA; Otrock ZK; Hudaib AR; Taher AT; Shamseddine AI
    Am J Hematol; 2007 Jan; 82(1):69-72. PubMed ID: 16947317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
    Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
    Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
    [No Abstract]   [Full Text] [Related]  

  • 15. Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia.
    Lee JH; Choi SJ; Lee JH; Park JH; Kim H; Joo YD; Lee WS; Zang DY; Kim HJ; Lee KH;
    Ann Hematol; 2006 Jun; 85(6):357-65. PubMed ID: 16575580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
    Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
    Leoni F; Ciolli S; Nozzoli C; Santini V; Fanci R; Rossi Ferrini P
    Haematologica; 2001 Jan; 86(1):104. PubMed ID: 11146581
    [No Abstract]   [Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor in post-remission therapy of acute myeloid leukemia.
    Sousa AB; Fernandes JP; Costa I; Ferreira G; Nunes O; Ribeiro P; Neves A; Cruz E; Aveiro F; Rodrigues AS; Bernardo M; Conduto A; Gonçalves AJ; Monteiro A; Sousa M; Soares VH; Veiga J; Gouveia J
    Hematol Cell Ther; 1998 Apr; 40(2):63-6. PubMed ID: 9615248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.